Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
36 hedge funds and large institutions have $7.4M invested in Lumos Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
3% less funds holding
Funds holding: 37 → 36 (-1)
19% less capital invested
Capital invested by funds: $9.16M → $7.4M (-$1.76M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$105K |
| 2 |
Millennium Management
New York
|
+$50.1K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$35.2K |
| 4 |
PAG
Paladin Advisory Group
Clive,
Iowa
|
+$15.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$361K |
| 2 |
Goldman Sachs
New York
|
-$220K |
| 3 |
SC
Shay Capital
New York
|
-$181K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$57.2K |
| 5 |
VF
Virtu Financial
New York
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $5.96K | +$6.26K | +1,788 | +14,900% |
|
|
WFA
27
West Financial Advisors
Des Moines,
Iowa
| $2.6K | – | – | – |
|
28
Morgan Stanley
New York
| $1.14K | – | – | – |
|
29
Group One Trading
Chicago,
Illinois
| $509 | – | – | – |
|
|
CCMW
30
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
| $331 | +$350 | +100 | New |
|
31
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $242 | – | – | – |
|
|
SSC
32
Syverson Strege & Co
West Des Moines,
Iowa
| $73 | – | – | – |
|
|
GRP
33
Global Retirement Partners
San Rafael,
California
| $37 | – | – | – |
|
|
LOIP
34
Live Oak Investment Partners
Austin,
Texas
| $36 | – | – | – |
|
|
35
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$361K | -100,000 | Closed |
|
|
SC
36
Shay Capital
New York
| – | -$181K | -50,000 | Closed |
|
|
KPF
37
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$57.2K | -15,836 | Closed |
|
|
VF
38
Virtu Financial
New York
| – | -$38K | -10,556 | Closed |
|
39
UBS Group
Zurich,
Switzerland
| – | -$7.34K | -2,033 | Closed |
|
40
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$38 | +11 | New |
|
LUMO Hedge Fund Activity: Q1 2023 in Review
36 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2023, worth a combined $7.4M — down 19% from $9.16M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LUMO and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 8 added.
The largest buyer was Greenwich Wealth Management, opening a new position worth an estimated $105K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $361K sold.
- 36 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $7.4M of Lumos Pharma, Inc. Common Stock stock for Q1 2023, down 19% quarter-over-quarter.
- 4 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -1 holder.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2023 was Greenwich Wealth Management, an estimated $105K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q1 2023 was T. Rowe Price Associates, an estimated $361K sold.
Based on aggregated 13F filings for Q1 2023.